Genetic Technologies Limited (NASDAQ: GENE) Stock Competitors & Peer Comparison
See GENE's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GENE and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GENE | $0.77 | +0.00% | 111.2M | -38.25 | -$0.02 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.64% |
| TMO | $675.00 | -0.50% | 249.1B | 29.09 | $23.16 | +0.27% |
| DHR | $224.49 | +0.32% | 157.8B | 28.14 | $7.98 | +0.64% |
| NTRA | $412.56 | +0.92% | 59.1B | -312.55 | -$1.32 | N/A |
| A | $172.79 | -0.03% | 48.8B | 29.74 | $5.81 | +0.59% |
| IQV | $270.37 | -1.69% | 44.4B | 22.24 | $12.13 | N/A |
| WAT | $433.54 | +0.75% | 42.6B | 31.71 | $13.68 | N/A |
| IDXX | $519.26 | +1.14% | 41B | 36.52 | $14.22 | N/A |
| ILMN | $270.00 | -1.42% | 40.9B | 53.68 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
GENE vs DHR-PB Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, GENE's ROE is -1.85%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, GENE is less volatile compared to DHR-PB. This indicates lower risk in terms of short-term price fluctuations for GENE.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
GENE vs TMO Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, TMO has a market cap of 249.1B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while TMO trades at $675.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas TMO's P/E ratio is 29.09. In terms of profitability, GENE's ROE is -1.85%, compared to TMO's ROE of +0.13%. Regarding short-term risk, GENE is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for GENE.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
GENE vs DHR Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, DHR has a market cap of 157.8B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while DHR trades at $224.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas DHR's P/E ratio is 28.14. In terms of profitability, GENE's ROE is -1.85%, compared to DHR's ROE of +0.08%. Regarding short-term risk, GENE is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for GENE.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
GENE vs NTRA Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, NTRA has a market cap of 59.1B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while NTRA trades at $412.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas NTRA's P/E ratio is -312.55. In terms of profitability, GENE's ROE is -1.85%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, GENE is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for GENE.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
GENE vs A Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, A has a market cap of 48.8B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while A trades at $172.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas A's P/E ratio is 29.74. In terms of profitability, GENE's ROE is -1.85%, compared to A's ROE of +0.20%. Regarding short-term risk, GENE is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for GENE.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
GENE vs IQV Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, IQV has a market cap of 44.4B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while IQV trades at $270.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas IQV's P/E ratio is 22.24. In terms of profitability, GENE's ROE is -1.85%, compared to IQV's ROE of +0.22%. Regarding short-term risk, GENE is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for GENE.Check IQV's competition here
Waters Corporation (NYSE: WAT)
GENE vs WAT Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, WAT has a market cap of 42.6B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while WAT trades at $433.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas WAT's P/E ratio is 31.71. In terms of profitability, GENE's ROE is -1.85%, compared to WAT's ROE of +0.02%. Regarding short-term risk, GENE is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for GENE.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
GENE vs IDXX Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, IDXX has a market cap of 41B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while IDXX trades at $519.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas IDXX's P/E ratio is 36.52. In terms of profitability, GENE's ROE is -1.85%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, GENE is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for GENE.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
GENE vs ILMN Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ILMN has a market cap of 40.9B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while ILMN trades at $270.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ILMN's P/E ratio is 53.68. In terms of profitability, GENE's ROE is -1.85%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, GENE is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for GENE.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
GENE vs MTD Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, MTD has a market cap of 30.5B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while MTD trades at $1,511.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas MTD's P/E ratio is 34.73. In terms of profitability, GENE's ROE is -1.85%, compared to MTD's ROE of -12.00%. Regarding short-term risk, GENE is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for GENE.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
GENE vs DGX Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, DGX has a market cap of 26.1B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while DGX trades at $236.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas DGX's P/E ratio is 23.30. In terms of profitability, GENE's ROE is -1.85%, compared to DGX's ROE of +0.14%. Regarding short-term risk, GENE is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for GENE.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
GENE vs LH Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while LH trades at $309.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas LH's P/E ratio is 18.37. In terms of profitability, GENE's ROE is -1.85%, compared to LH's ROE of +0.12%. Regarding short-term risk, GENE is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for GENE.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
GENE vs GH Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, GH has a market cap of 23.7B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while GH trades at $177.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas GH's P/E ratio is -50.56. In terms of profitability, GENE's ROE is -1.85%, compared to GH's ROE of +2.11%. Regarding short-term risk, GENE is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for GENE.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
GENE vs EXAS Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas EXAS's P/E ratio is -95.37. In terms of profitability, GENE's ROE is -1.85%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, GENE is similarly volatile compared to EXAS. This indicates similar risk in terms of short-term price fluctuations for GENE.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
GENE vs MEDP Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while MEDP trades at $618.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas MEDP's P/E ratio is 36.28. In terms of profitability, GENE's ROE is -1.85%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, GENE is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for GENE.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
GENE vs ILMNV Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ILMNV's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to ILMNV's ROE of N/A. Regarding short-term risk, GENE is similarly volatile compared to ILMNV. This indicates similar risk in terms of short-term price fluctuations for GENE.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
GENE vs RVTY Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, RVTY has a market cap of 16.9B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while RVTY trades at $151.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas RVTY's P/E ratio is 28.24. In terms of profitability, GENE's ROE is -1.85%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, GENE is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for GENE.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
GENE vs PKI Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas PKI's P/E ratio is 41.45. In terms of profitability, GENE's ROE is -1.85%, compared to PKI's ROE of +0.03%. Regarding short-term risk, GENE is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for GENE.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
GENE vs CRL Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CRL has a market cap of 14.1B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while CRL trades at $292.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CRL's P/E ratio is 29.61. In terms of profitability, GENE's ROE is -1.85%, compared to CRL's ROE of -0.08%. Regarding short-term risk, GENE is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for GENE.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
GENE vs ICLR Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while ICLR trades at $172.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ICLR's P/E ratio is 14.06. In terms of profitability, GENE's ROE is -1.85%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, GENE is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for GENE.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
GENE vs QGEN Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, QGEN has a market cap of 9.1B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while QGEN trades at $44.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas QGEN's P/E ratio is 18.25. In terms of profitability, GENE's ROE is -1.85%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, GENE is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for GENE.Check QGEN's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
GENE vs BLLN Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BLLN has a market cap of 5.7B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while BLLN trades at $123.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BLLN's P/E ratio is 175.83. In terms of profitability, GENE's ROE is -1.85%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, GENE is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for GENE.Check BLLN's competition here
RadNet, Inc. (NASDAQ: RDNT)
GENE vs RDNT Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while RDNT trades at $70.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas RDNT's P/E ratio is 153.89. In terms of profitability, GENE's ROE is -1.85%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, GENE is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for GENE.Check RDNT's competition here
GRAIL Inc. (NASDAQ: GRAL)
GENE vs GRAL Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, GRAL has a market cap of 5.4B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while GRAL trades at $126.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas GRAL's P/E ratio is -12.83. In terms of profitability, GENE's ROE is -1.85%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, GENE is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for GENE.Check GRAL's competition here
Sotera Health Company (NASDAQ: SHC)
GENE vs SHC Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while SHC trades at $18.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas SHC's P/E ratio is 19.10. In terms of profitability, GENE's ROE is -1.85%, compared to SHC's ROE of +0.27%. Regarding short-term risk, GENE is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for GENE.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
GENE vs SYNH Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas SYNH's P/E ratio is 61.40. In terms of profitability, GENE's ROE is -1.85%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, GENE is less volatile compared to SYNH. This indicates lower risk in terms of short-term price fluctuations for GENE.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
GENE vs VCYT Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while VCYT trades at $45.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas VCYT's P/E ratio is 22.72. In terms of profitability, GENE's ROE is -1.85%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, GENE is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for GENE.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
GENE vs CDNA Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while CDNA trades at $63.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CDNA's P/E ratio is 75.81. In terms of profitability, GENE's ROE is -1.85%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, GENE is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for GENE.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
GENE vs OLK Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas OLK's P/E ratio is -96.59. In terms of profitability, GENE's ROE is -1.85%, compared to OLK's ROE of -0.07%. Regarding short-term risk, GENE is less volatile compared to OLK. This indicates lower risk in terms of short-term price fluctuations for GENE.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
GENE vs WGS Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, WGS has a market cap of 2.6B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while WGS trades at $88.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas WGS's P/E ratio is 245.56. In terms of profitability, GENE's ROE is -1.85%, compared to WGS's ROE of -0.39%. Regarding short-term risk, GENE is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for GENE.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
GENE vs PSNL Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, PSNL has a market cap of 1.8B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while PSNL trades at $16.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas PSNL's P/E ratio is -15.10. In terms of profitability, GENE's ROE is -1.85%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, GENE is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for GENE.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
GENE vs OPK Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while OPK trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas OPK's P/E ratio is -6.07. In terms of profitability, GENE's ROE is -1.85%, compared to OPK's ROE of -0.06%. Regarding short-term risk, GENE is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for GENE.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
GENE vs CSTL Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while CSTL trades at $35.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CSTL's P/E ratio is -54.26. In terms of profitability, GENE's ROE is -1.85%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, GENE is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for GENE.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
GENE vs FLGT Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, FLGT has a market cap of 630.5M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while FLGT trades at $22.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas FLGT's P/E ratio is 2220.00. In terms of profitability, GENE's ROE is -1.85%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, GENE is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for GENE.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
GENE vs GRALV Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas GRALV's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to GRALV's ROE of N/A. Regarding short-term risk, GENE is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for GENE.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
GENE vs NEO Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, NEO has a market cap of 496.7M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while NEO trades at $19.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas NEO's P/E ratio is 148.69. In terms of profitability, GENE's ROE is -1.85%, compared to NEO's ROE of -0.06%. Regarding short-term risk, GENE is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for GENE.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
GENE vs CO Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CO's P/E ratio is 5.06. In terms of profitability, GENE's ROE is -1.85%, compared to CO's ROE of +0.11%. Regarding short-term risk, GENE is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for GENE.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
GENE vs MYGN Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, MYGN has a market cap of 393.8M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while MYGN trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas MYGN's P/E ratio is -32.08. In terms of profitability, GENE's ROE is -1.85%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, GENE is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for GENE.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
GENE vs FLDM Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas FLDM's P/E ratio is -4.74. In terms of profitability, GENE's ROE is -1.85%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, GENE is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for GENE.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
GENE vs BDSX Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BDSX has a market cap of 236.9M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while BDSX trades at $29.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BDSX's P/E ratio is -9.18. In terms of profitability, GENE's ROE is -1.85%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, GENE is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for GENE.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
GENE vs XGN Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, XGN has a market cap of 210.7M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while XGN trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas XGN's P/E ratio is -10.77. In terms of profitability, GENE's ROE is -1.85%, compared to XGN's ROE of -1.22%. Regarding short-term risk, GENE is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for GENE.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
GENE vs FRNM Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, FRNM has a market cap of 130.4M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while FRNM trades at $15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas FRNM's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to FRNM's ROE of N/A. Regarding short-term risk, GENE is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for GENE.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
GENE vs GTH Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas GTH's P/E ratio is -1.11. In terms of profitability, GENE's ROE is -1.85%, compared to GTH's ROE of -1.01%. Regarding short-term risk, GENE is less volatile compared to GTH. This indicates lower risk in terms of short-term price fluctuations for GENE.Check GTH's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
GENE vs IMDX Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, IMDX has a market cap of 126.6M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while IMDX trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas IMDX's P/E ratio is -2.63. In terms of profitability, GENE's ROE is -1.85%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, GENE is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for GENE.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
GENE vs SERA Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, SERA has a market cap of 77.9M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while SERA trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas SERA's P/E ratio is -3.14. In terms of profitability, GENE's ROE is -1.85%, compared to SERA's ROE of -0.47%. Regarding short-term risk, GENE is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for GENE.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
GENE vs PRPO Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, PRPO has a market cap of 42.2M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while PRPO trades at $23.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas PRPO's P/E ratio is -36.38. In terms of profitability, GENE's ROE is -1.85%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, GENE is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for GENE.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
GENE vs QUCY Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, QUCY has a market cap of 31.4M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while QUCY trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas QUCY's P/E ratio is -0.06. In terms of profitability, GENE's ROE is -1.85%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, GENE is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for GENE.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
GENE vs MDXH Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, MDXH has a market cap of 29M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while MDXH trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas MDXH's P/E ratio is -0.77. In terms of profitability, GENE's ROE is -1.85%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, GENE is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for GENE.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
GENE vs AKU Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas AKU's P/E ratio is -0.13. In terms of profitability, GENE's ROE is -1.85%, compared to AKU's ROE of -5.32%. Regarding short-term risk, GENE is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for GENE.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
GENE vs BNR Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BNR has a market cap of 19.7M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while BNR trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BNR's P/E ratio is -21.38. In terms of profitability, GENE's ROE is -1.85%, compared to BNR's ROE of -0.13%. Regarding short-term risk, GENE is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for GENE.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
GENE vs CEMI Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CEMI's P/E ratio is -0.63. In terms of profitability, GENE's ROE is -1.85%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, GENE is similarly volatile compared to CEMI. This indicates similar risk in terms of short-term price fluctuations for GENE.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
GENE vs ENZ Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ENZ's P/E ratio is -2.24. In terms of profitability, GENE's ROE is -1.85%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, GENE is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for GENE.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
GENE vs PMD Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas PMD's P/E ratio is -5.24. In terms of profitability, GENE's ROE is -1.85%, compared to PMD's ROE of -0.32%. Regarding short-term risk, GENE is similarly volatile compared to PMD. This indicates similar risk in terms of short-term price fluctuations for GENE.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
GENE vs ME Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ME's P/E ratio is -0.03. In terms of profitability, GENE's ROE is -1.85%, compared to ME's ROE of -42.03%. Regarding short-term risk, GENE is similarly volatile compared to ME. This indicates similar risk in terms of short-term price fluctuations for GENE.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
GENE vs MYNZ Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, GENE's ROE is -1.85%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, GENE is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for GENE.Check MYNZ's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
GENE vs CHEK Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CHEK's P/E ratio is -0.43. In terms of profitability, GENE's ROE is -1.85%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, GENE is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for GENE.Check CHEK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
GENE vs BIAFW Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BIAFW has a market cap of 9.6M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while BIAFW trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BIAFW's P/E ratio is 1.02. In terms of profitability, GENE's ROE is -1.85%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, GENE is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for GENE.Check BIAFW's competition here
Centogene N.V. (NASDAQ: CNTG)
GENE vs CNTG Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CNTG's P/E ratio is -0.23. In terms of profitability, GENE's ROE is -1.85%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, GENE is similarly volatile compared to CNTG. This indicates similar risk in terms of short-term price fluctuations for GENE.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
GENE vs ADVB Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ADVB has a market cap of 8.8M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while ADVB trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ADVB's P/E ratio is -58.00. In terms of profitability, GENE's ROE is -1.85%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, GENE is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for GENE.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
GENE vs NDRA Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while NDRA trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas NDRA's P/E ratio is -0.90. In terms of profitability, GENE's ROE is -1.85%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, GENE is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for GENE.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
GENE vs APDN Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas APDN's P/E ratio is -0.10. In terms of profitability, GENE's ROE is -1.85%, compared to APDN's ROE of -7.23%. Regarding short-term risk, GENE is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for GENE.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
GENE vs NVTA Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas NVTA's P/E ratio is -0.00. In terms of profitability, GENE's ROE is -1.85%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, GENE is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for GENE.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
GENE vs LMDX Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas LMDX's P/E ratio is -0.01. In terms of profitability, GENE's ROE is -1.85%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, GENE is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for GENE.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
GENE vs LMDXW Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, GENE's ROE is -1.85%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, GENE is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for GENE.Check LMDXW's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
GENE vs BIAF Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BIAF has a market cap of 3.3M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while BIAF trades at $7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BIAF's P/E ratio is -0.93. In terms of profitability, GENE's ROE is -1.85%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, GENE is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for GENE.Check BIAF's competition here
DermTech, Inc. (NASDAQ: DMTK)
GENE vs DMTK Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas DMTK's P/E ratio is -0.04. In terms of profitability, GENE's ROE is -1.85%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, GENE is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for GENE.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
GENE vs NOTV Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas NOTV's P/E ratio is -0.03. In terms of profitability, GENE's ROE is -1.85%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, GENE is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for GENE.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
GENE vs SQL Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas SQL's P/E ratio is -0.40. In terms of profitability, GENE's ROE is -1.85%, compared to SQL's ROE of -30.46%. Regarding short-term risk, GENE is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for GENE.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
GENE vs AWH Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas AWH's P/E ratio is -0.09. In terms of profitability, GENE's ROE is -1.85%, compared to AWH's ROE of +1.62%. Regarding short-term risk, GENE is similarly volatile compared to AWH. This indicates similar risk in terms of short-term price fluctuations for GENE.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
GENE vs HTGM Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas HTGM's P/E ratio is -0.03. In terms of profitability, GENE's ROE is -1.85%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, GENE is similarly volatile compared to HTGM. This indicates similar risk in terms of short-term price fluctuations for GENE.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
GENE vs BIOC Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BIOC's P/E ratio is -0.01. In terms of profitability, GENE's ROE is -1.85%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, GENE is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for GENE.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
GENE vs SQLLW Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, GENE's ROE is -1.85%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, GENE is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for GENE.Check SQLLW's competition here
iSpecimen Inc. (NASDAQ: ISPC)
GENE vs ISPC Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, ISPC has a market cap of 175K. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while ISPC trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas ISPC's P/E ratio is -0.04. In terms of profitability, GENE's ROE is -1.85%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, GENE is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for GENE.Check ISPC's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
GENE vs WGSWW Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, GENE's ROE is -1.85%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, GENE is similarly volatile compared to WGSWW. This indicates similar risk in terms of short-term price fluctuations for GENE.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
GENE vs OCDX Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas OCDX's P/E ratio is -42.28. In terms of profitability, GENE's ROE is -1.85%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, GENE is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for GENE.Check OCDX's competition here
Danaher Corporation (NYSE: DHR-PA)
GENE vs DHR-PA Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, GENE's ROE is -1.85%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, GENE is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for GENE.Check DHR-PA's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
GENE vs MEUSW Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas MEUSW's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, GENE is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for GENE.Check MEUSW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
GENE vs BNGOW Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas BNGOW's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, GENE is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for GENE.Check BNGOW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
GENE vs NDRAW Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas NDRAW's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, GENE is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for GENE.Check NDRAW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
GENE vs PRXL Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas PRXL's P/E ratio is 42.97. In terms of profitability, GENE's ROE is -1.85%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, GENE is less volatile compared to PRXL. This indicates lower risk in terms of short-term price fluctuations for GENE.Check PRXL's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
GENE vs CHEKZ Comparison September 2026
Genetic Technologies Limited (NASDAQ: GENE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GENE stands at 111.2M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, GENE is priced at $0.77 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GENE currently has a P/E ratio of -38.25, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, GENE's ROE is -1.85%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, GENE is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for GENE.Check CHEKZ's competition here